Hess G, Arnold W, Möller B, Gahl G M, Meyer zum Büschenfelde K H
Med Microbiol Immunol. 1980 Feb;168(1):25-34. doi: 10.1007/BF02121649.
Intercalating agents, some of them in clinical use, were tested for their ability to inhibit the hepatitis B virus specific DNA polymerase reaction. Ethidium bromide was shown to be the strongest inhibitor among the compounds tested. Compounds in clinical use inhibited the DNA polymerase test only at high concentrations. The inhibitory activity of all compounds tested was increased when the MgCl2 content in the reaction mixture was lowered. UV absorption studies presented no evidence that this effect was due to complex formation of magnesium and the individual compounds. The therapeutic significance of these findings is not certain and needs further work.
插入剂（其中一些已在临床中使用）被测试其抑制乙肝病毒特异性DNA聚合酶反应的能力。在测试的化合物中，溴化乙锭被证明是最强的抑制剂。临床使用的化合物仅在高浓度时才抑制DNA聚合酶测试。当反应混合物中的MgCl2含量降低时，所有测试化合物的抑制活性均增强。紫外线吸收研究没有提供证据表明这种效应是由于镁与单个化合物形成复合物所致。这些发现的治疗意义尚不确定，需要进一步研究。
